Call for Abstracts

2nd Global Conference on Myositis

GCOM 2017 Abstract Submission Instructions - Abstract submission deadline is 11:59PM Eastern USA time, December 16, 2016

Steps and Instructions:

  1. Submitting an Abstract

    • Use standard abbreviations. A list of acronyms for many common rheumatology terms has been developed by an international group of rheumatology journal editors and may be used - see
    • Place special or unusual abbreviations in parentheses after the first time the full word appears.
    • Do not use any abbreviations in the title of the abstract.
    • Use numerals to indicate numbers, except when beginning sentences.
  2. Abstract Character Limit

    • Abstract Title Character Limit: 250 characters which EXCLUDES spaces.
    • Abstract Body Character Limit: 2,750 characters, which EXCLUDES the title, names of authors/coauthors, authors' affiliations, spacing and disclosures.
    • Abstract Image, Table and/or Graphic Upload Limit: There is a limit of a total of 3 images, tables and/or graphic uploads per submission. Each uploaded table and/or graphic will decrease the character count by 250 characters from the total limit allowed.
    • Abstracts exceeding the character limit will be considered 'incomplete'.
    • Abstracts marked 'incomplete' at the close of the submission deadline will be ineligible for consideration.
  3. Abstract Title

    • Take special care when entering your title as it may be published exactly as submitted. Titles should be brief, clearly indicating the nature of the presentation.
    • Title character limit is 250 characters.
    • Do not include trial group names or trial group acronyms in the abstract title, as they are not included in the unified list of acronyms approved by the principal journal editors in the field of rheumatology.
    • When entering the abstract title online, use mixed case (do not use all caps OR all lower case) and do not put a period at the end of the title.
    • Correct: This Is a Properly Formatted Abstract Title
    • Incorrect: This is an improperly formatted abstract title
  4. Acronym Usage

    • Abstract Title: GCOM will only publish commonly used acronyms included in the unified list of acronyms approved by the principal journal editors in the field of rheumatology.
    • Abstract Body: Acronyms may remain in the body of the abstract and in the author list. Acronyms not included in the unified list of acronyms are acceptable for inclusion in the abstract body.
  5. Authors

    • There is no limit to the number of authors that may be included in the author block.
    • All presenting authors and co-authors must disclose any relevant financial relationship(s) at the time of abstract submission in the section entitled 'All Sources of Funding for this Project for All Authors'.
    • See the abstract disclosure policy and authorship criteria below for additional author identification details and instructions.
  6. Authorship Criteria

    • Substantial contributions to study conception and design.
    • Substantial contributions to acquisition of data.
    • Substantial contributions to analysis and interpretation of data.
    • Drafting the article or revising it critically for important intellectual content.
    • Final approval of the version of the article to be published.
    • Other critical study activities (specify).
    • List authors of a trial group as "(insert first/last name of author) on behalf of (insert trial name)".
    • When adding a study group or trial name as an author, please use the 'Add Group' button.
  7. Content

    • Do not use new technical words, laboratory slang, words not defined in dictionaries, or abbreviations or terminology not consistent with internationally accepted guidelines.
    • Define any abbreviations the first time they are used.
    • Refer to the unified list of acronyms for recommendations on acceptable terms for scientific communication.
    • Omit all names and geographical references in the body of the abstract.
    • Organize content as follows:
      • Background: Background or Statement of Purpose
      • Methods: Methods, materials and analytical procedure used*
      • Results: Summary of the results in sufficient detail to support conclusion
      • Conclusion: Conclusions reached (do not state "results will be discussed")

        *Please Note: In order to make the description of patients as clear as possible and to facilitate comparisons with other studies, the Methods section should include, whenever possible, a short paragraph detailing the proportion of patients who satisfy the ACR or other classification criteria for the particular disease described.
  8. Image, Tables and Graphics

    • Up to three images are allowed, however each image/table counts as 250 characters towards your maximum of 2750 total characters.
    • The characters in the table do NOT count towards this limit - each table is worth exactly 250 characters.
    • The maximum allowable size of each image is 2.5 MB. Images will be accepted as PNG, JPG, or GIF files.
    • If you have a table, please upload it as an image. This will help us ensure consistent and accurate output of your abstract at time of publication.
  9. Disclosure Policy

    • If no financial support or commercial relationships exists, individual MUST STATE that NONE exist by clicking 'No' to reflect that the question was asked and answered.
    • The ACCME defines relevant financial relationships as financial relationships in any amount occurring within the past 12 months of both the individual and/or spouse/partner (i.e., see Relevant Financial Relationships below).
        *Relevant Financial Relationships
      1. Stock options or bond holdings in a for-profit corporation or self-directed pension plan
      2. Research grants
      3. Employment (full or part-time)
      4. Ownership or partnership
      5. Consulting fees or other remuneration
      6. Non-remunerative positions of influence, such as officer, board member, trustee or public spokesperson
      7. Receipt of royalties
      8. Speakers' bureau
      9. Other

        None: has no relevant financial relationship to disclose

        Commercial interest is considered any entity producing marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.

        Conflict of Interest exists when individuals (within 12 months, including the spouse/partner) have a relevant financial relationship with a commercial interest and the opportunity to affect the content of the presentation about the products or services of that commercial interest.
  10. Disclosure Statement Submission

    Presenting Authors are permitted to enter the disclosure information on the behalf of each co-author during the on-line abstract submission process.

  11. Institutional Review Board Affirmation

    An Institutional Review Board is charged with protecting the rights and welfare of people involved in research. If your research involved human subjects you will be required to check a box during the submission process to attest that you have received the appropriate IRB approval.

  12. Multiple Submissions of Same Study

    The same study should not be submitted as multiple abstracts. Therefore, if the abstracts in question are not different enough to be considered separate studies (specifically, if they address the same research question or present the same results), they may all be rejected.

  13. Online Revisions

    • Proofread abstracts carefully to avoid errors before they are submitted. Your abstract, if selected, may be published in print and electronic versions exactly as submitted.
    • You may return to the online abstract submission site to revise your abstract until midnight US Eastern time, December 16. After this time, the submission site will close and changes or withdrawals will not be possible.
    • Should a submission contain errors or the omission of contributing author names after the deadline, GCOM may withdraw the abstract.
  14. Presentation Formats

    • Abstracts are considered for either oral presentation or poster presentation.
    • As English is the designated language for the meeting, the presenting author is required to speak English when presenting.
    • If your abstract can only be presented as a poster, please check the appropriate box in the 'Abstract Title' section of the submission site.
  15. Product Name Usage

    • If a product has received FDA approval, the proprietary drug name may appear once in parentheses in the title only. The nonproprietary (generic/scientific) name must be used in the body of the abstract.
    • If a product has not received FDA approval, only the nonproprietary name may be used in the title and abstract body.
    • In the case of biosimilars:
      • The approved reference product for a biosimilar should be referred to by the nonproprietary name of the biopharmaceutical preceded by the term "reference" (e.g., "reference adalimumab" for Humira) in the abstract body.
      • The proprietary drug name of the reference product may appear once in parentheses in the title only.
      • If a biosimilar has not received FDA approval, only the unique nonproprietary name may be used in the title and abstract content. If no unique nonproprietary name exists for a biosimilar, the investigational drug name must be used, not the trade name.

      • Example title: "Review of Research for ABP 501, a Biosimilar Candidate for Reference Adalimumab (Humira)"

        Example text reference: ABP 501 (reference adalimumab)

    • Failure to comply will result in disqualification of your submission.
  16. Study Design Abstract Submissions

    A study design abstract could be appropriate for submission if, like any other abstract submission, it describes a hypothesis, description of methodology, data, interpretation of data, etc. (e.g., one study design could be compared to another).

  17. Study Sponsor Statements

    • For abstracts about studies that were funded by a pharmaceutical company, biotech company or other commercial enterprise, a "Role of the Study Sponsor" statement must be added on step 4 of the submission process. For multiple sponsor statements, click the 'Add Study Sponsor' button.
    • This statement describes for the learner the part played by the commercial entity in the conduct and reporting of the study. IMPORTANT: This applies only to commercial enterprises (e.g., pharmaceutical or biotech companies; device manufacturing companies).
    • It does not apply to government entities such as the National Institute of Health (NIH) or its equivalent funding agencies in other countries or to public or private foundations.
  18. General Instructions

    No names or titles should be included in the abstract text. Names will be automatically hidden during the abstract review process and will be automatically inserted and properly formatted upon publication.

    Presenting authors will be automatically informed of the unique ID numbers and passwords assigned to their abstracts. Abstracts may be viewed and modified at any time between submission and the deadline, using the assigned ID# and password.

Begin a submission to the following:

New Submissions Closed

Technical Support

For help in submitting an abstract online, Contact technical support.